Design of HSV-1 Based Vaccines for Cancer

Many replication-incompetent HSV-1-based vectors have also been used either as potential anti-herpes vaccines, as well as vaccine vectors for other pathogens in murine and simian models. Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for HSV-1 based vaccines. We guarantee the finest results for our customers all over the world.

Herpes Simplex Viruses (HSV)

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the herpesvirus family, Herpesviridae, that infect humans. Both HSV-1 (which produces most cold sores) and HSV-2 (which produces most genital herpes) are ubiquitous and contagious. They can be spread when an infected person is producing and shedding the virus.

Recombinant non-replicative Herpes simplex viruses (HSV) are potential vectors for several applications in human health. These include:

• Delivery and expression of human genes to central nervous system (CNS) cells;
• Selective destruction of cancer cells;
• Prophylaxis and immunotherapy against tumors;
• Prophylaxis against HSV-mediated and other infectious diseases.

Each application requires a different kind of vector and, in principle, different kinds of genetic engineering.

HSV-1 Based Vaccines for Cancer

The use of HSV vectors for prophylaxis against viral infections and tumors requires genetically stable mutants, incapable of replicating in CNS and of spreading in immunocompromised individuals, unable to reactivate, not transmissible from immunized vaccinated individuals to contacts; however, the recombinant viral vectors have to retain their immunogenicity in order to elicit protective immunity against diseases in their hosts. A large number of defective viruses have been proposed for immunization on the ground that although they cannot produce infectious progeny and fundamentally make proteins only in the set of initially infected cells, the presentation of viral antigens and/or transgene, synthesized ex novo in these cells, to the host’s immune system is able to elicit long-lived and potent cellular and humoral immune responses. Various non-replicative HSV-1-based vectors have been successfully used either as potential anti-herpes vaccines in murine model or as vaccine vectors in murine and simian models.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

Reference

1. Berto, E. (2005). “Development and application of replication-incompetent HSV-1-based vectors.” Gene Ther 12.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.